The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery

The high frequency of RAS mutations in human cancers (33%) has stimulated intense interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major focus of these efforts is centered on inhibitors of components involved in Ras downstream effector signaling. In particular, m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Neel, Nicole F., Martin, Timothy D., Stratford, Jeran K., Zand, Tanya P., Reiner, David J., Der, Channing J.
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2011
Materias:
Monographs
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128631/
https://ncbi.nlm.nih.gov/pubmed/21779498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601911407329
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares